Free Trial
→ Trump’s Plan To Cheat History (From Porter & Company) (Ad)tc pixel
NASDAQ:SYBX

Synlogic Q3 2026 Earnings Date & Estimates

Synlogic logo
$0.96 -0.09 (-8.57%)
As of 10/30/2026 01:53 PM Eastern

Synlogic is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 12, 2026 at 4:00 PM ET.

Research:ProfileEarnings History

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Synlogic in Q3 2026

Synlogic is expected to post earnings of -$5.80 per share. In the same quarter a year earlier Synlogic reported -$0.19 per share. Synlogic last reported on November 13, 2025, posting -$0.19 per share and missing the -$0.11 consensus estimate. Synlogic has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$5.80
Prior-Year EPS
-$0.19

Recent Track Record

Last Reported
Q3 2025
Last Quarter EPS
-$0.19 (Missed by -$0.08)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Synlogic Q3 2026 Earnings FAQ

Synlogic (NASDAQ:SYBX) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Synlogic's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Synlogic to post earnings of -$5.80 per share for Q3 2026.

Synlogic Earnings Headlines

Synlogic (NASDAQ:SYBX) Shares Break Below 50-Day Moving Average - Time to Sell?
October 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31142031
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Varex Imaging Corporation (Nasdaq – VREX), Synlogic, Inc. (OTC – SYBX), Bowman Consulting Group Ltd. (Nasdaq – BWMN), Nathan's Famous, Inc. (Nasdaq – NATH)
August 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352812/0/en/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-varex-imaging-corporation-nasdaq-vrex-synlogic-inc-otc-sybx-bowman-consulting-group-ltd-nasdaq-.html
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
 |  Porter & Company (Ad)
SYBX Stock Alert: Halper Sadeh LLC is Investigating Whether Synlogic, Inc. is Obtaining a Fair Price for its Shareholders
August 10, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/08/10/10427797.htm
Synlogic and Caldera Therapeutics announce merger and $278 million private placement
July 29, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/synlogic-and-caldera-therapeutics-announce-merger-and-278-million-private-placement/ar-AA28Zdef
Synlogic Challenges Nasdaq Delisting Notice
November 26, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/synlogic-challenges-nasdaq-delisting-notice?utm_source=marketbeat.com&utm_medium=referral
See More Synlogic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synlogic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synlogic and other key companies, straight to your email.

About Synlogic

Synlogic (NASDAQ:SYBX) was a clinical-stage biopharmaceutical company focused on developing medicines based on synthetic biology. Its platform used genetically engineered probiotic bacteria, known as Synthetic Biotics, designed to carry out specific therapeutic functions inside the gastrointestinal tract.

The company’s research programs targeted metabolic and gastrointestinal disorders. Its leading candidates included SYNB1934, an investigational treatment intended to help break down phenylalanine in people with phenylketonuria, and SYNB8802, which was designed to consume oxalate in the gut for the potential treatment of enteric hyperoxaluria. Synlogic also evaluated other engineered bacterial therapies for rare diseases and metabolic conditions.

Founded in 2013 and headquartered in Cambridge, Massachusetts, Synlogic advanced its programs through preclinical research and clinical trials. In 2023, the company announced that it was discontinuing clinical development of its lead programs and pursuing strategic alternatives, including a review of its operations and assets. As a result, Synlogic’s status and activities have differed from those of an actively operating clinical-stage biotechnology company.

View Synlogic Profile
Earnings Tools